Acyclovir Cream, 5%, is the generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The product is available by prescription only and is associated with mild side effects such as nausea.
“Approval of our Acyclovir Cream, 5%, marks another milestone along our path toward providing more accessible, complex generic formulations to patients and to the U.S. healthcare system.
Also read | Intas launches immunity booster to fight C-19
Acyclovir Cream, 5%, represents one of our complex drug products launched this year, which demonstrates the strength of our pipeline and the depth of our manufacturing capabilities” stated Chirag and Chintu Patel, Co-Chief Executive Officers.
According to IQVIA, a leading healthcare data and analytics provider, US annual sales for Acyclovir Cream, 5%, for the 12 months ended September 2020 were approximately $67 million.